Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study

Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study

Abstract Background Patients with rheumatoid arthritis (RA) are at an increased risk of developing certain cancers and infections compared with the general population. Biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) are effective treatment options for RA, but limit...

Full description

Bibliographic Details
Main Authors: Teresa A. Simon, Maarten Boers, Marc Hochberg, Nicole Baker, Mary L. Skovron, Nitesh Ray, Sanket Singhal, Samy Suissa, Andres Gomez-Caminero
Format: Article
Language:English
Published: BMC 2019-11-01
Series:Arthritis Research & Therapy
Subjects:
Abatacept
Real-world data
Claims
Infections
Malignancies
Rheumatoid arthritis
Online Access:http://link.springer.com/article/10.1186/s13075-019-1992-x

Internet

http://link.springer.com/article/10.1186/s13075-019-1992-x

Similar Items